🏛️ Verified NIH Record • Updated 2026-02-10
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (NCT05980806)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Karyopharm Therapeutics Inc
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Who can join: Review the eligibility criteria below.
Location: City of Hope - Duarte Main Site — Duarte, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (70 Sites)
- City of Hope - Duarte Main Site — Duarte, California
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology — Columbia, Maryland
- Weill Cornell Medicine NewYork-Presbyterian — New York, New York
- Duke University — Durham, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- MD Anderson — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- UZ Gent — Ghent,
- UZ Leuven - Campus Gasthuisberg — Leuven,
- University Multiprofile Hospital for Active Treatment Sveti George - Base 1 — Plovdiv,
- University Hospital Sv.Ivan Rilski - Sofia — Sofia,
- University Multiprofile Hospital for Active Treatment Aleksandrovska — Sofia,
- Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia — Sofia,
- University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD Department of Clinical Hematology — Stara Zagora,
- Research Institute of the McGill University Health Centre — Montreal, Quebec
- Fakultní nemocnice Olomouc — Olomouc,
- Aarhus Universitetshospital — Aarhus N, Central Jutland
- Institut Bergonié — Bordeaux, Aquitaine
- Centre Hospitalier Lyon-Sud — Pierre-Bénite, Auvergne-Rhône-Alpes
- CHU Tours, Hôpital Bretonneau Service d'Hématologie thérapie cellulaire — Tours, Indre-et-Loire
- Chu De Nîmes - Institut De Cancérologie Du Gard — Nîmes, Occitanie
- Centre Hospitalier Universitaire d'Angers — Angers, Pays de la Loire Region
- Hôpital Saint-Louis — Paris,
- Hôpital Cochin — Paris,
- Centre Hospitalier Universitaire de Saint-Etienne — Saint-Priest-en-Jarez,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.